Bowave Pharmaceuticals Reports Up to 99% Reduction in HAE Attack Rates with siRNA Therapy BW-20805 in Phase II Clinical Trial Update
Argo
RNAi Drug Developer
Source: Pharma News Brief
As of the data cutoff date, the HAE attack rate decreased by 99% in the 600 mg Q24W group, with 83% (5/6) of patients remaining attack-free; it decreased by 93% in the 300 mg Q24W group, with 60% (3/5) of patients being attack-free; and it decreased by 95% in the 300 mg Q12W group, with 60% (3/5) of patients remaining attack-free during the period. Plasma PKK levels exhibited a rapid and significant decline. On Day 85, the mean reduction in plasma PKK levels exceeded 94% in the combined 300 mg dose group and reached approximately 96% in the 600 mg dose group. Throughout the 169-day follow-up period, PKK inhibition remained above 90% across all three study groups. BW-20805 demonstrated favorable safety and tolerability across the three dose groups, comprising a total of 18 subjects. No serious adverse events or severe adverse events related to the study drug were observed during the study. Furthermore, no treatment-emergent adverse events led to subject withdrawal from the study or death. All injection site reactions were mild and transient, resolving spontaneously without the need for medical intervention.
BW-20805YessiRNA Therapy Targeting Plasma Kallikrein (PKK)By inhibiting PKK expression, it prevents HAE attacks and demonstrates significant potential for long-acting therapy. PKK and its active form, kallikrein, are well-validated therapeutic targets in the current treatment landscape of HAE.
Disclaimer:
The content of this article is for reference only and does not constitute investment advice. Investors who act on this information do so at their own risk. We maintain a neutral stance regarding the statements and viewpoints expressed herein, and provide no express or implied warranties as to the accuracy, reliability, or completeness of the content contained. Readers are advised to use this information for reference purposes only and assume full responsibility for any consequences arising from its use.
ICNS 2026
Booths are in high demand—reserve yours now!
Scan the QR Code to Consult Now
Tel: 13816031174
(Same as WeChat)
Sponsorship forms include, but are not limited toSpeaking slots, exhibition booths, color pages in the conference program, dinner sponsorship, promotional materials for conference supplies, etc.